Neurodegenerative Diseases: New Insights and
Therapeutic Opportunities to advance discussion about therapies for
Alzheimer's disease among world's leading researchers
TORONTO and CAMBRIDGE, MA, June 5,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN)
(OTCQB: ARFXF), a biotechnology company focused on the discovery
and development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases, will
present key data on monoclonal antibody PMN310 for Alzheimer's
disease at the Keystone Symposium on Neurodegenerative Diseases:
New Insights and Therapeutic Opportunities. For nearly fifty years,
the conference has attracted the world's most accomplished
researchers in neurodegenerative diseases to discuss future
directions in therapy and care. ProMIS' Chief Development Officer
Dr. Johanne Kaplan will present the
company's lead therapeutic candidate PMN310 which demonstrates high
selectivity for the toxic forms of amyloid beta implicated as a
root cause of Alzheimer's disease.
In the poster, "Selective targeting of HHQK conformational
epitope in amyloid-beta oligomer species by PMN310, a monoclonal
antibody rationally designed for greater therapeutic potency in
Alzheimer's disease," Dr. Kaplan will present data for PMN310 that
show:
- Superior selectivity for amyloid beta (AßOs) toxic
oligomers.
- Potential to safely administer high doses of PMN310 with a
reduced risk of brain swelling or ARIA.
- Potential to show greater therapeutic potency compared with
other Aß-directed antibodies.
"Evidence continues to mount, showing that amyloid-beta toxic
oligomers (AßO) - not amyloid plaque - are the key target for
Alzheimer's disease therapy," said Dr. Johanne Kaplan. "The current therapeutic gap
lies in how to effectively neutralize the toxic oligomer without
wasting antibody on non-toxic forms of the protein. We're pleased
our data will help inform discussions regarding future directions
among the world's most accomplished researchers. Our data will
demonstrate the unique ability of the ProMIS discovery platform to
generate antibodies that bind the toxic species of amyloid beta
while preserving healthy forms of the protein. Humanized PMN310 is
currently in advanced preclinical development."
The conference, Keystone Symposia on Molecular and Cellular
Biology, Neurodegenerative Diseases: New Insights and Therapeutic
Opportunities, takes place on June 16-20,
2019 at Keystone Resort in Keystone, Colorado. For more information,
please visit www.keystonesymposia.org.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines - ProMIS and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn and listen to the podcast, Saving
Minds, at iTunes or Spotify.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-presents-lead-program-for-alzheimers-disease-at-prestigious-keystone-symposia-scientific-conference-300861947.html
SOURCE ProMIS Neurosciences Inc.